Overview

Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement

Status:
Completed

Trial end date:
2021-11-05

Target enrollment:

Participant gender:

Summary

This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs. dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac CT imaging) and cerebral embolization (documented with brainDiffusion-weighted (DW) magnetic resonance (MR) imaging) in patients without an absolute indication for chronic oral anticoagulation (OAC) after successful transcatheter aortic valve replacement(TAVR).

Phase:

Phase 4

Details

Lead Sponsor:

Duk-Woo Park, MD
Seung-Jung Park

Collaborators:

CardioVascular Research Foundation, Korea
Daiichi Sankyo Korea Co., Ltd.

Treatments:

Edoxaban